OMACOR CAPSULES

$129.00
No tax

OMACOR CAPSULES - 28 pcs

Quantity

 

Security policy (edit with Customer reassurance module)

 

Delivery policy (edit with Customer reassurance module)

 

Return policy (edit with Customer reassurance module)

Transparent soft gelatin capsule size 20, the contents of the capsule - oily liquid light yellow color.
Contains omega-3 class polyunsaturated fatty acids - eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) - essential (essential) fatty acids.

Mechanism of action

Lipolipidemic. Omacor reduces the content of triglycerides by reducing the concentration of VLDL, in addition, it actively affects hemostasis, reducing the synthesis of thromboxane A2 and slightly increasing the clotting time of blood.
Pharmacokinetics: During and after the absorption of omega-3 fatty acids, there are 3 main ways of their metabolism:
- fatty acids are first delivered to the liver, where they are included in the various categories of lipoproteins and sent to peripheral lipid stores;
- phospholipids of cell membranes are replaced by phospholipids of lipoproteins, after which fatty acids act as precursors of various eicosanoids;
- most fatty acids are oxidized in order to meet energy needs.
The concentration of omega-3 fatty acids - EPA and DHA - in plasma phospholipids corresponds to the concentration of EPA and DHA included in the cell membranes.
Pharmacodynamics: Delays the synthesis of triglycerides in the liver, since EPA and DHA inhibit the esterification of other fatty acids.Reducing the level of triglycerides also contributes to reducing the amount of free fatty acids (peroxisomes of beta-oxidation of fatty acids increase) involved in the synthesis of triglycerides. Inhibition of their synthesis lowers the level of VLDL.
The increase in HDL is very small and not permanent. It is significantly less than after taking fibrates.
The results of observations (within 3.5 years) of patients taking 1 g of Omacor per day showed a significant reduction in the combined index, including all-cause mortality, as well as non-fatal myocardial infarction and stroke.

Indications and usage

Secondary prevention of myocardial infarction (in combination with other standard methods of treatment with statins, antiplatelet agents, beta-blockers, ACE inhibitors).
Hypertriglyceridemia: endogenous hypertriglyceridemia - as a supplement to the diet with its lack of effectiveness:
type IV (as monotherapy),
types IIb / III (in combination with statins - in the case when the concentration of triglycerides remains high).

Overdosage

Symptoms: possible appearance of side effects or increase their severity.

Special notes

In connection with a moderate increase in bleeding time (when taking a high dose - 4 caps.), Monitoring of patients undergoing anticoagulant therapy is required, and, if necessary, a corresponding dose adjustment of the anticoagulant. Conducting this therapy does not preclude the need for routine control in the treatment of such patients.The increase in bleeding time in patients with an increased risk of hemorrhage (as a result of severe injury, surgery, etc.) should be taken into account. Experience in the study of secondary endogenous hypertriglyceridemia (especially uncontrollable diabetes mellitus) is very limited. There is no clinical experience regarding the treatment of hypertriglyceridemia in combination with fibrates. When taking Omacor, a moderate increase in the activity of liver transaminases is possible. In patients with impaired liver function (especially when taking a high dose - 4 caps.) Requires regular monitoring of liver function (AST and ALT). Information about the use of the drug Omacor in children, elderly patients older than 70 years or in patients with impaired liver function is not available.

Does not affect the ability to drive a car and maintain cars.

Drug Interactions

With simultaneous use with oral anticoagulants - the risk of increased bleeding time. Appointment of Omacor along with Warfarin does not lead to any hemorrhagic complications. However, when combined with Omakor and warfarin, or if Omakor stops treatment, it is necessary to control prothrombin time.
Not recommended for simultaneous use with fibrates.

Storage conditions

List B. The drug should be stored in a dry place inaccessible to children at a temperature not higher than 25 ° C. Do not freeze. Shelf life - 3 years.

Pharmacy sales terms

42 Items